Ratcliffe Peter John — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Ratcliffe Peter John has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
Profile
Peter John Ratcliffe is a British physician-scientist recognized for his work on cellular oxygen sensing and the hypoxia-inducible factor (HIF) pathway. He was a co-recipient of the Nobel Prize in Physiology or Medicine in 2019 for discoveries concerning how cells sense and adapt to oxygen availability. He has held prominent academic roles and has contributed to the biotech/pharmaceutical sector through leadership positions on company boards. In the context of SEC filings dated 2026-05-28, he is identified as a director of Immunocore Holdings plc, reflecting his role as a non-executive director with the company.
Peter John Ratcliffe is a British physician-scientist recognized for his work on cellular oxygen sensing and the hypoxia-inducible factor (HIF) pathway. He was a co-recipient of the Nobel Prize in Physiology or Medicine in 2019 for discoveries concerning how cells sense and adapt to oxygen availability. He has held prominent academic roles and has contributed to the biotech/pha…
How many SEC Form 4 filings has Ratcliffe Peter John submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Where can I see all of Ratcliffe Peter John's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
